I-Mab (NASDAQ: IMAB) announced significant expansion of its givastomig program, a CLDN18.2 x 4-1BB bispecific antibody for cancer treatment. The company plans to initiate a global randomized Phase 2 study in Q1 2026 for first-line metastatic gastric cancers, combining givastomig with immunochemotherapy.
Key developments include Phase 1b dose expansion data expected in Q1 2026, expansion into additional cancer types including biliary tract cancer (BTC) and pancreatic ductal adenocarcinoma (PDAC), and new investigator-initiated trials in neoadjuvant settings. The company also announced leadership changes, with Wei Fu appointed as Executive Chairman and Dr. Sean Cao joining as Chief Business Development Officer.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.